Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GMAB
GMAB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GMAB News
Genmab's TEPKINLY Approved by EU for Follicular Lymphoma
1d ago
NASDAQ.COM
TEPKINLY® Approved in Europe for Relapsed Follicular Lymphoma Treatment
1d ago
Newsfilter
European Commission Approves Tepkinly Label Expansion for Blood Cancer Therapy
21h ago
seekingalpha
Genmab's Tepkinly Approved by European Commission
1d ago
Yahoo Finance
AbbVie's Epkinly Shows Significant Survival Benefits in Lymphoma Patients
Jun 29 2026
seekingalpha
Genmab Phase 3 Study Success
Jun 29 2026
Yahoo Finance
Epcoritamab Combination Therapy Shows Significant Survival Improvement
Jun 29 2026
Newsfilter
Genmab Major Shareholder Announcement
Jun 15 2026
Newsfilter
Genmab Reports Positive Clinical Trial Results for Epcoritamab
Jun 14 2026
NASDAQ.COM
Epcoritamab Shows Significant Efficacy in Elderly DLBCL Patients
Jun 13 2026
Newsfilter
New Data on Epcoritamab Combination Therapy for Lymphoma Released
Jun 11 2026
Newsfilter
Latest Wall Street Rating Updates
May 26 2026
CNBC
Genmab Major Shareholder Announcement
May 08 2026
Newsfilter
Genmab Reports 25% Revenue Growth in Q1
May 07 2026
seekingalpha
Genmab to Announce Q1 Earnings on May 7
May 06 2026
seekingalpha
Latest Rating Changes on Wall Street
Apr 22 2026
CNBC
Show More News
